Brief: Nicox’S NCX 4251 Mississippi Phase 2B Blepharitis Trial Reaches 50% Enrollment

Nicox SA

23/04/2021 06:34

April 23 (Reuters) - NICOX SA  NCOX.PA :
    * NICOX’S NCX 4251 MISSISSIPPI PHASE 2B BLEPHARITIS TRIAL
REACHES
50% ENROLLMENT
    * MILESTONE SHOWS TRIAL REMAINS ON TRACK FOR TOP-LINE
RESULTS IN
Q4 2021
    * 102 PATIENTS RANDOMIZED AS OF APRIL 22, 2021, OUT OF A
TARGET OF
200
    * PRIMARY OUTCOME MEASURE IS PROPORTION OF PATIENTS
ACHIEVING
COMPLETE CURE IN EYELID REDNESS, EYELID DEBRIS AND EYELID
DISCOMFORT
    * CONTINUE TO CLOSELY WATCH SPREAD AND IMPACT OF COVID-19
PANDEMIC
AND WE WILL PROVIDE AN UPDATE OF ANY DELAYS
    * FOLLOWING ENCOURAGING RESULTS SEEN IN EARLIER DANUBE PHASE
2
TRIAL, WE HOPE TO DEMONSTRATE POTENTIAL FOR NCX 4251 IN
BLEPHARITIS WITH THIS LARGER TRIAL
    * SHOULD NCX 4251 MEET THIS PRIMARY EFFICACY ENDPOINT FOR
BLEPHARITIS, MISSISSIPPI TRIAL COULD REPRESENT FIRST OF TWO
PIVOTAL TRIALS NEEDED TO SUPPORT AN NDA IN U.S. FOR TREATMENT OF
ACUTE EXACERBATIONS OF BLEPHARITIS

Source text for Eikon:  ID:nGNEQWxkb 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))